ABBV Jan 2023 80.000 call
| Previous close | 57.76 |
| Open | 54.09 |
| Bid | 51.30 |
| Ask | 54.50 |
| Strike | 80.00 |
| Expiry date | 2023-01-20 |
| Day's range | 54.09 - 54.09 |
| Contract range | N/A |
| Volume | |
| Open interest | 290 |
- Motley Fool
Is AbbVie Stock a Top Pick for 2022?
Treasury yields are rising, and the Federal Reserve is expected to raise interest rates multiple times in 2022. In the case of AbbVie (NYSE: ABBV), look no further. AbbVie is a global prescription drug developer, manufacturer, and distributor that was spun off from parent company Abbott Labs back in 2013.
- Motley Fool
3 Clinical Trials to Watch in the First Half of 2022
In this Motley Fool Live video recorded on Jan. 12, 2022, Fool contributors Keith Speights and Brian Orelli discuss three clinical trials especially worth watching in the first half of 2022. Which clinical results are you especially looking forward to seeing? Brian Orelli: Arena (NASDAQ: ARNA), the ticker there is A-R-N-A, it expects data from a phase 3 study of etrasimod in patients with ulcerative colitis.
- PR Newswire
U.S. FDA Approves Second Indication for SKYRIZI® (risankizumab-rzaa) to Treat Adults with Active Psoriatic Arthritis
AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved SKYRIZI® (risankizumab-rzaa) for the treatment of adults with active psoriatic arthritis (PsA), a systemic inflammatory disease that affects the skin and joints and impacts approximately 30 percent of patients with psoriasis.1,4-7
